ReviewJournal of clinical medicine2024
Breaking the Dogma of Intravenous Treatment for Infective Endocarditis: A Systematic Review and Meta-Analysis.
Review in Journal of clinical medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Partial Oral Antibiotic Therapy for Infective Endocarditis: A Practical Review of Current Evidence and Guidelines.Pathogens (Basel, Switzerland) · 2026Review
- Should We Extend the Use of Oral Antibiotics in Infective Endocarditis? The ENDO-ORAL Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Oral versus intravenous antibiotics: Oral antibiotics are more cost-effective and may be safer than intravenous antibiotics for most infections in stable adults.African journal of primary health care & family medicine · 2025Review
- Oral Therapy for Infective Endocarditis: Where Do We Stand?Pathogens (Basel, Switzerland) · 2025Review
- Mapping Review of the Correlations Between Periodontitis, Dental Caries, and Endocarditis.Dentistry journal · 2025Review
- Beyond antibiotic prophylaxis: A scoping review of infective endocarditis prevention in the device era.International journal of immunopathology and pharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.